Related Experiment Video
Updated: Feb 11, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Humanization of bone and bone marrow in an orthotopic site reveals new potential therapeutic targets in osteosarcoma
Ferdinand Wagner1, Boris M Holzapfel2, Jacqui A McGovern3
1Institute of Health and Biomedical Innovation, Queensland University of Technology (QUT), 60 Musk Avenue, Kelvin Grove, QLD 4059, Brisbane, Australia; Department of Pediatric Surgery, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University Munich, Lindwurmstraße 4, 80337 Munich, Germany; Department of Orthopedics for the University of Regensburg, Asklepios Klinikum Bad Abbach, Kaiser-Karl V.-Allee 3, 93077 Bad Abbach, Germany.
Background:
Existing preclinical murine models often fail to predict effects of anti-cancer drugs. In order to minimize interspecies-differences between murine hosts and human bone tumors of in vivo xenograft platforms, we tissue-engineered a novel orthotopic humanized bone model.
Methods:
Orthotopic humanized tissue engineered bone constructs (ohTEBC) were fabricated by 3D printing of medical-grade polycaprolactone scaffolds, which were seeded with human osteoblasts and embedded within polyethylene glycol-based hydrogels containing human umbilical vein endothelial cells (HUVECs). Constructs were then implanted at the femur of NOD-scid and NSG mice. NSG mice were then bone marrow transplanted with human CD34 + cells. Human osteosarcoma (OS) growth was induced within the ohTEBCs by direct injection of Luc-SAOS-2 cells. Tissues were harvested for bone matrix and marrow morphology analysis as well as tumor biology investigations. Tumor marker expression was analyzed in the humanized OS and correlated with the expression in 68 OS patients utilizing tissue micro arrays (TMA).
Results:
After harvesting the femurs micro computed tomography and immunohistochemical staining showed an organ, which had all features of human bone. Around the original mouse femur new bone trabeculae have formed surrounded by a bone cortex. Staining for human specific (hs) collagen type-I (hs Col-I) showed human extracellular bone matrix production. The presence of nuclei staining positive for human nuclear mitotic apparatus protein 1 (hs NuMa) proved the osteocytes residing within the bone matrix were of human origin. Flow cytometry verified the presence of human hematopoietic cells. After injection of Luc-SAOS-2 cells a primary tumor and lung metastasis developed. After euthanization histological analysis showed pathognomic features of osteoblastic OS. Furthermore, the tumor utilized the previously implanted HUVECS for angiogenesis. Tumor marker expression was similar to human patients. Moreover, the recently discovered musculoskeletal gene C12orf29 was expressed in the most common subtypes of OS patient samples.
Conclusion:
OhTEBCs represent a suitable orthotopic microenvironment for humanized OS growth and offers a new translational direction, as the femur is the most common location of OS. The newly developed and validated preclinical model allows controlled and predictive marker studies of primary bone tumors and other bone malignancies.
Insights
We developed a novel humanized bone model to better predict anti-cancer drug efficacy. This tissue-engineered orthotopic humanized bone construct (ohTEBC) successfully supports human osteosarcoma growth and metastasis in mice.
Area of Science:
- Biomedical Engineering
- Oncology
- Tissue Engineering
Background:
- Preclinical murine models often fail to accurately predict anti-cancer drug effects in humans.
- Interspecies differences between murine hosts and human bone tumors limit the utility of current in vivo xenograft platforms.
- A novel orthotopic humanized bone model was engineered to minimize these differences.
Purpose of the Study:
- To develop and validate a novel tissue-engineered orthotopic humanized bone construct (ohTEBC).
- To create a more predictive preclinical model for human bone tumors, specifically osteosarcoma (OS).
- To enable controlled and predictive marker studies for primary bone tumors and other bone malignancies.
Main Methods:
- Fabrication of ohTEBCs using 3D printed scaffolds, human osteoblasts, and hydrogels with human umbilical vein endothelial cells (HUVECs).
- Implantation into mouse femurs, followed by human CD34+ cell transplantation and induction of human osteosarcoma growth.
- Analysis of bone matrix, marrow morphology, tumor biology, and correlation of tumor marker expression with patient data.
Main Results:
- The engineered constructs exhibited features of human bone, including human extracellular matrix production and human osteocytes.
- The model supported human osteosarcoma growth, angiogenesis via implanted HUVECs, and metastasis.
- Tumor marker expression in the model closely mirrored that of human osteosarcoma patients, including the gene C12orf29.
Conclusions:
- The ohTEBCs provide a suitable orthotopic microenvironment for humanized osteosarcoma growth.
- This validated preclinical model offers a new translational direction for studying bone malignancies, particularly osteosarcoma.
- The model facilitates controlled and predictive marker studies for bone tumors.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Bone Structure
Bone Remodeling
Compact Bone
Compact bone, also called cortical bone, is the denser, stronger of the two types of bone tissue. It is found under the periosteum and in the diaphyses of long bones, where it provides support and protection. The microscopic structural unit of compact bone is called an osteon, or haversian system. Each osteon is composed of concentric rings of calcified...
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
The Hyoid Bone

